Last reviewed · How we verify

NCT05672407

The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery

Withdrawn Phase 4 Last updated 21 September 2023
What this trial tests

Phase 4 trial testing Tranexamic acid in Eyelid Diseases. Withdrawn.

Timeline
1 September 2023
Primary endpoint
1 June 2026
1 June 2026

Quick facts

Lead sponsorUniversity of Miami
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposesupportive care
Start date1 September 2023
Primary completion1 June 2026
Estimated completion1 June 2026

Drugs / interventions tested

Conditions studied

Sponsor

University of Miami

Who can join

18 and older, any sex, with Eyelid Diseases or Periorbital Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the effect of tranexamic acid, a medication that helps reduce bleeding, in patients undergoing surgeries around their eyes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tranexamic acid

Trials testing the same drug.

Other recruiting trials for Eyelid Diseases

Currently open trials in the same condition.

Other University of Miami trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing